(Q54167081)

25 May 2018

title

Dipyridamole combined with tumor necrosis factor-alpha enhances inhibition of proliferation in human tumor cell lines. (English)

1 reference

25 May 2018

author name string

N Suzuki

1

1 reference

25 May 2018

S Sekiya

2

1 reference

25 May 2018

I Sugano

3

1 reference

25 May 2018

T Kojima

4

1 reference

25 May 2018

H Yamamori

5

1 reference

25 May 2018

Y Takakubo

6

1 reference

25 May 2018

publication date

1 August 1995

1 reference

25 May 2018

number of pages

9

1 reference

Japanese Journal of Cancer Research

inferred from page(s)

published in

1 reference

25 May 2018

volume

86

1 reference

25 May 2018

issue

8

1 reference

25 May 2018

page(s)

761-769

1 reference

25 May 2018

Growth arrest of the breast cancer cell line, T47D, by TNF alpha; cell cycle specificity and signal transduction

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

Involvement of antipain-sensitive protease activity in suppression of UV-mutagenicity by human interferon-α

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro.

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

Tumor necrosis factor production by human sarcoid alveolar macrophages

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

Phase I study of recombinant tumor necrosis factor in cancer patients.

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

Platelet aggregation inhibitors in the prevention of myocardial infarction: the results of prospective studies

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

Phase-I trial of intravenous continuous infusion of tumor necrosis factor in advanced metastatic carcinomas

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

Tumor necrosis factor: still a promising agent

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

Establishment of a human skin squamous cell carcinoma cell line (SCC-1CB) in vitro and its characteristics

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

A phase I trial of recombinant human tumor necrosis factor and interferon-gamma: effects of combination cytokine administration in vivo

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

Phase I study of a combination of recombinant tumor necrosis factor-alpha and recombinant interferon-gamma in cancer patients

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

Recent advances in the management of biotherapy-related side effects: fatigue

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

Central nervous system toxicity of interferons and other cytokines

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II.

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

Clinical studies with TNF.

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

A phase II combination trial with recombinant human tumor necrosis factor and gamma interferon in patients with colorectal cancer

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

Recombinant tumour necrosis factor alpha administered subcutaneously or intramuscularly for treatment of advanced malignant disease: a phase I trial

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

Phase I Evaluation of Recombinant Tumor Necrosis Factor Given in Combination With Recombinant Interferon-Gamma

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

Enhancement of an anti-tumor effect of interferon by dipyridamole in established human malignant melanoma cell lines

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

The molecular action of tumor necrosis factor-alpha

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

Clinical effect of intra-arterial tumor necrosis factor-alpha for malignant glioma

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

Augmentation of antineoplastic effects by the combination of recombinant human tumor necrosis factor and mitoxantrone on primary culture of human ovarian cancer cells

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

A phase I pharmacokinetic study of recombinant human tumor necrosis factor administered by a 5-day continuous infusion

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

Cytokines in tumour therapy

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

Dipyridamole enhances an anti-proliferative effect of interferon in various types of human tumor cells

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

The current status of toxicity protectants in cancer therapy

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

An endotoxin-induced serum factor that causes necrosis of tumors

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

Establishment and some biological characteristics of human hepatoma cell lines

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

Synergistic cytotoxic effects of tumor necrosis factor, interferon-gamma and tamoxifen on breast cancer cell lines

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

A phase II trial of PALA + dipyridamole in patients with advanced soft-tissue sarcoma.

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

Synergistic Cytotoxicity of Recombinant Human TNF and Various Anti-Cancer Drugs

26 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920906

Comparative studies of the biological activities of human tumor necrosis factor and its derivatives

30 November 2018

1 reference

12 December 2020

In vitro analysis of the anticancer potential of tumor necrosis factor in combination with cisplatin

1 reference

12 December 2020

Effects of interferon on the human clonal cell line, RSa: inhibition of macromolecular synthesis

1 reference

12 December 2020

Tumor necrosis factor acts synergistically with autocrine interferon-beta and increases interferon-beta mRNA levels in human fibroblasts

1 reference

12 December 2020

Early phase II study of interferon-alpha and tumor necrosis factor-alpha combination in patients with advanced cancer

1 reference

12 December 2020

Lack of in vitro synergy between etoposide and cis-diamminedichloroplatinum(II)

1 reference

12 December 2020

Anti-tumor effects of tumor necrosis factor in combination with chemotherapeutic agents

1 reference

12 December 2020

1 reference

12 December 2020

The synergistic antitumor effect of natural-human TNF and anticancer drugs

1 reference

12 December 2020

Cockayne syndrome with delayed recovery of RNA synthesis after ultraviolet irradiation but normal ultraviolet survival

1 reference

12 December 2020

Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo

1 reference

12 December 2020

Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly

1 reference

12 December 2020

[Dipyridamole and ischemic heart disease]

1 reference

12 December 2020

10.1111/J.1349-7006.1995.TB02466.X

Identifiers

DOI

1 reference

25 May 2018

PMC publication ID

5920906

1 reference

25 May 2018

PubMed publication ID

7559100

1 reference

25 May 2018